Renata Mojzikova

Renata Mojzikova

Auto-generated profile, based on publicly available information

Renata Mojzikova

Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MGMehrdad Ghashghaeinia
Mehrdad Ghashghaeinia
DGDaniela Giustarini
Daniela Giustarini
PKPavla Koralkova
Pavla Koralkova
MKMartin Köberle
Martin Köberle
KAKousi Alzoubi
Kousi Alzoubi
UMUlrich Mrowietz
Ulrich Mrowietz
In mature erythrocytes, glucose-6-phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase (6PGDH) yield NADPH, a crucial cofactor of the enzyme glutathione reductase (GR) converting glutathione disulfide (GSSG) into its reduced state (GSH). GSH is essential for detoxification processes in and survival of erythrocytes. We explored whether the anti-inflammatory compounds Bay 11–7082, parthenolide and dimethyl fumarate (DMF) were able to completely deplete a common target (GSH), and to impair the function of upstream enzymes of GSH recycling and replenishment. Treatment of erythrocytes with Bay 11–7082, parthenolide or DMF led to concentration-dependent eryptosis resulting from complete depletion of GSH. GSH depletion was due to strong inhibition of G6PDH activity. Bay 11–7082 and DMF, but not parthenolide, were able to inhibit the GR activity. This approach “Inhibitors, Detection of their common target that is completely depleted or inactivated when pharmacologically relevant concentrations of each single inhibitor are applied, Subsequent functional analysis of upstream enzymes for this target” (IDS), can be applied to a broad range of inhibitors and cell types according to the selected target. The specific G6PDH inhibitory effect of these compounds may be exploited for the treatment of human diseases with high NADPH and GSH consumption rates, including malaria, trypanosomiasis, cancer or obesity.

18 February 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RMRenata Mojzikova
Renata Mojzikova
PKPavla Koralkova
Pavla Koralkova
DHDusan Holub
Dusan Holub
ZZZuzana Zidova
Zuzana Zidova
DPDagmar Pospisilova
Dagmar Pospisilova
VDVladimir Divoky
Vladimir Divoky

1 January 2016 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ICIlja Czolkos
Ilja Czolkos
EDEva Dock
Eva Dock
ETErik Tønning
Erik Tønning
JCJakob Christensen
Jakob Christensen
MWMargrethe Winther-Nielsen
Margrethe Winther-Nielsen
JEJenny Emnéus
Jenny Emnéus

1 March 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
RMRenata Mojzikova
Renata Mojzikova
PKPavla Koralkova
Pavla Koralkova
DHDusan Holub
Dusan Holub
ZSZuzana Saxova
Zuzana Saxova
DPDagmar Pospisilova
Dagmar Pospisilova
VDVladimir Divoky
Vladimir Divoky

1 January 2014 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
ZZZuzana Zidova
Zuzana Zidova
KKKatarina Kapralova
Katarina Kapralova
PKPavla Koralkova
Pavla Koralkova
RMRenata Mojzikova
Renata Mojzikova
DDDalibor Dolezal
Dalibor Dolezal
MPMonika Horvathova nee Priwitzerova
Monika Horvathova nee Priwitzerova
Deficiency of the divalent metal transporter 1 (DMT1) leads to hypochromic microcytic anemia. We have previously shown that DMT1 deficiency impairs erythroid differentiation and induces apoptosis of erythroid cells. Here we analyzed metabolic processes and survival of mature erythrocytes in order to address potential involvement of erythrocyte defect in the pathophysiology of the disease. FACS analysis was used to determine the half-life of erythrocytes (CFSE fluorescence), phosphatidylserine exposure (Annexin V binding), cytosolic Ca(2+) (Fluo3/AM fluorescence) and reactive oxygen species (ROS; DCF fluorescence). Enzyme activities were determined by standard biochemical methods. The concentration of ATP and ADP was measured on HPLC-MS/MS. We observed an accelerated clearance of CFSE-labeled DMT1-mutant erythrocytes from circulating blood when compared to wild-type erythrocytes. In vitro, DMT1-mutant erythrocytes showed significantly increased Annexin V binding after exposure to hyperosmotic shock and glucose depletion. Despite exaggerated anti-oxidative defense, higher ROS levels were present in DMT1-mutant erythrocytes. Accelerated anaerobic glycolysis and reduced ATP/ADP ratio detected in DMT1-mutant erythrocytes indicate enhanced demand for ATP. We propose that DMT1 deficiency negatively affects metabolism and life span of mature erythrocytes; two other aspects of defective erythropoiesis which contribute to the pathophysiology of the disease.

7 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
JŠJán Štetka
Ján Štetka
JGJan Gursky
Jan Gursky
JVJulie Liñan Velasquez
Julie Liñan Velasquez
RMRenata Mojzikova
Renata Mojzikova
PVPavla Vyhlidalova
Pavla Vyhlidalova
VDVladimir Divoky
Vladimir Divoky
Inflammatory and oncogenic signaling, both known to challenge genome stability, are key drivers of BCR-ABL-positive chronic myeloid leukemia (CML) and JAK2 V617F-positive chronic myeloproliferative neoplasms (MPNs). Despite similarities in chronic inflammation and oncogene signaling, major differences in disease course exist. Although BCR-ABL has robust transformation potential, JAK2 V617F-positive polycythemia vera (PV) is characterized by a long and stable latent phase. These differences reflect increased genomic instability of BCR-ABL-positive CML, compared to genome-stable PV with rare cytogenetic abnormalities. Recent studies have implicated BCR-ABL in the development of a "mutator" phenotype fueled by high oxidative damage, deficiencies of DNA repair, and defective ATR-Chk1-dependent genome surveillance, providing a fertile ground for variants compromising the ATM-Chk2-p53 axis protecting chronic phase CML from blast crisis. Conversely, PV cells possess multiple JAK2 V617F-dependent protective mechanisms, which ameliorate replication stress, inflammation-mediated oxidative stress and stress-activated protein kinase signaling, all through up-regulation of RECQL5 helicase, reactive oxygen species buffering system, and DUSP1 actions. These attenuators of genome instability then protect myeloproliferative progenitors from DNA damage and create a barrier preventing cellular stress-associated myelofibrosis. Therefore, a better understanding of BCR-ABL and JAK2 V617F roles in the DNA damage response and disease pathophysiology can help to identify potential dependencies exploitable for therapeutic interventions.